Sarilumab by Regeneron Pharmaceuticals for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval

Sarilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Polyarticular Juvenile Idiopathic Arthritis (PJIA).

J&J unveils PhIIa data of oral antiviral for dengue fever prevention

Johnson & Johnson’s oral antiviral has shown hints of activity in a Phase IIa human challenge trial for the prevention of mosquito-borne disease dengue fever,

October 21, 2023

California Legislature passes Gov. Newsom’s proposal to retool mental health services act

The California Legislature passed a pair of bills greenlighting Gov. Gavin Newsom’s campaign to build 10,000 new beds and housing units and increase drug addiction

September 15, 2023

A dose of reality on adult vaccinations

The number of children who received their routine vaccinations declined during the pandemic, so public health officials have been focusing on getting kids back up

May 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.